MA27121A1 - Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol - Google Patents

Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol

Info

Publication number
MA27121A1
MA27121A1 MA25462A MA25462A MA27121A1 MA 27121 A1 MA27121 A1 MA 27121A1 MA 25462 A MA25462 A MA 25462A MA 25462 A MA25462 A MA 25462A MA 27121 A1 MA27121 A1 MA 27121A1
Authority
MA
Morocco
Prior art keywords
purin
diol
derivatives
tetrahydrofuran
tétrahvdrofuran
Prior art date
Application number
MA25462A
Other languages
English (en)
Inventor
Peter Charles Cousins Richard
Cox Brian
Ellis Frank
Joan Dyke Hazel
Victoria Geden Joanna
Swanson Stephen
David Bays Dr
Chan Chuen
Mary Cook Caroline
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27121(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en
Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27121A1 publication Critical patent/MA27121A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Abstract Dérivés 2-(Purin-9-yl)-tétrahvdrofuran-3,4-diol Sont proposés suivant l'invention des composés nouveaux de formule (I) oé R1, R2 et R3 sont tels que définis dans la description, des procédés en vue de leur préparation, des compositions les contenant, et leur emploi en thérapie pour le traitement de maladies inflammatoires.
MA25462A 1998-02-14 1999-02-12 Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol MA27121A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803169.3A GB9803169D0 (en) 1998-02-14 1998-02-14 Chemical compounds
GBGB9813533.8A GB9813533D0 (en) 1998-06-23 1998-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
MA27121A1 true MA27121A1 (fr) 2005-01-03

Family

ID=26313119

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25462A MA27121A1 (fr) 1998-02-14 1999-02-12 Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol

Country Status (31)

Country Link
US (1) US6610665B1 (fr)
EP (1) EP1056759B1 (fr)
JP (1) JP2002503669A (fr)
KR (1) KR20010082512A (fr)
AP (1) AP2000001881A0 (fr)
AR (1) AR017457A1 (fr)
AT (1) ATE223429T1 (fr)
AU (1) AU757156B2 (fr)
BR (1) BR9907886A (fr)
CA (1) CA2319009A1 (fr)
CO (1) CO4990969A1 (fr)
DE (1) DE69902758T2 (fr)
DK (1) DK1056759T3 (fr)
EA (1) EA200000759A1 (fr)
EE (1) EE200000358A (fr)
ES (1) ES2183516T3 (fr)
HR (1) HRP20000538A2 (fr)
HU (1) HUP0100702A3 (fr)
IL (1) IL137402A0 (fr)
IS (1) IS5576A (fr)
MA (1) MA27121A1 (fr)
NO (1) NO20004045L (fr)
NZ (1) NZ505812A (fr)
PE (1) PE20000270A1 (fr)
PL (1) PL342396A1 (fr)
PT (1) PT1056759E (fr)
SK (1) SK12002000A3 (fr)
SV (1) SV1999000016A (fr)
TR (1) TR200002355T2 (fr)
WO (1) WO1999041267A1 (fr)
YU (1) YU50800A (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) * 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US6495528B1 (en) 1998-06-23 2002-12-17 Smithkline Beecham Corporation 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006028618A1 (fr) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation Analogues d'adenosine de propynyle 2-polycyclique presentant des groupes 5'-ribose modifies presentant une activite agoniste de a2a
WO2006023272A1 (fr) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation Analogues de 2-polycyclique propynyle adenosine presentant une activite agoniste de a2a
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2625664C (fr) 2005-10-21 2016-01-05 Novartis Ag Molecules organiques
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
NZ620020A (en) 2009-08-17 2015-06-26 Intellikine Llc Heterocyclic compounds and uses thereof
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
WO2013038362A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
EP2834246B1 (fr) 2012-04-03 2021-07-28 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
PE20000270A1 (es) * 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US6495528B1 (en) * 1998-06-23 2002-12-17 Smithkline Beecham Corporation 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives

Also Published As

Publication number Publication date
EP1056759B1 (fr) 2002-09-04
AU2623599A (en) 1999-08-30
PT1056759E (pt) 2003-01-31
YU50800A (sh) 2003-04-30
AP2000001881A0 (en) 2000-09-30
ES2183516T3 (es) 2003-03-16
WO1999041267A1 (fr) 1999-08-19
NZ505812A (en) 2002-03-01
TR200002355T2 (tr) 2000-11-21
HK1032062A1 (en) 2001-07-06
DK1056759T3 (da) 2003-01-06
ATE223429T1 (de) 2002-09-15
NO20004045D0 (no) 2000-08-11
EE200000358A (et) 2001-10-15
JP2002503669A (ja) 2002-02-05
DE69902758D1 (de) 2002-10-10
CA2319009A1 (fr) 1999-08-19
CO4990969A1 (es) 2000-12-26
IS5576A (is) 2000-07-25
DE69902758T2 (de) 2003-05-15
EP1056759A1 (fr) 2000-12-06
HRP20000538A2 (en) 2000-12-31
HUP0100702A3 (en) 2003-01-28
SK12002000A3 (sk) 2001-07-10
KR20010082512A (ko) 2001-08-30
PL342396A1 (en) 2001-06-04
AR017457A1 (es) 2001-09-05
NO20004045L (no) 2000-08-11
BR9907886A (pt) 2000-10-17
SV1999000016A (es) 1999-10-27
HUP0100702A2 (hu) 2002-01-28
AU757156B2 (en) 2003-02-06
US6610665B1 (en) 2003-08-26
EA200000759A1 (ru) 2001-04-23
IL137402A0 (en) 2001-07-24
PE20000270A1 (es) 2000-05-20

Similar Documents

Publication Publication Date Title
MA27121A1 (fr) Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol
MA24729A1 (fr) Macrolides nouveaux.
MA27316A1 (fr) Derives d'indoline-phenylsulfonamide
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
FR2435471A1 (fr) Derives de dihydropyridine, procedes d'obtention et compositions pharmaceutiques en contenant
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
ATE253586T1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivat
TNSN92008A1 (fr) Steroides-esters nouveaux
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26696A1 (fr) Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
BG104729A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
ATE178044T1 (de) Inhibitoren des arginin-ketoamid-enzyms
TNSN01028A1 (fr) Derives de purine nouveaux, procede pour leur preparation et compositions les contenant
TNSN00203A1 (fr) Derives de purine nouveaux, procede pour leur preparation et des compositions les contenant
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97145A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2430412A1 (fr) Derives substitues de propanolamine utiles comme medicaments et procede de leur preparation
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
EA200301063A1 (ru) Фармацевтические агенты для лечения ганв и микроаденом
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
TNSN88041A1 (fr) NOUVEAUX β-D-PHENYL THIOXYLOSIDES, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE